Canaccord Genuity analyst Sumant Kulkarni maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $107 to $113.
Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $113
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.